RESUMO
The human pathogen Candida albicans can grow as a biofilm on host tissues and on the surfaces of different prosthetic devices in a patient's body. Various studies have reported that biofilms formed by C. albicans are resistant to most of the currently used antibiotics including the widely prescribed drug, fluconazole. As such, novel strategies for the treatment of drug-resistant biofilms are required. Drug repositioning or the use of drugs outside their unique indication has the potential to radically change drug development. We have tested 16 anticancer drugs for their activities against C. albicans. For the first time, we are reporting repositioning of anticancer drugs as potential antibiofilm agents in C. albicans. Nine categories of drugs with different chemical modes of action effectively inhibited biofilms at a concentration range of 0.25-4 mg/mL, establishing their potential for the inhibition of biofilms. Human genes targeted by these drugs show significant identity with their homologous genes in C. albicans at the amino acid as well as nucleotide levels. This study indicates that anticancer drugs could be potential candidates for repositioning as anti-Candida biofilm agents.
